T1	PROC 46 81	Estudio piloto abierto aleatorizado
T2	CHEM 110 119	sarilumab
#1	AnnotatorNotes T2	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 87 106	evaluar la eficacia
#2	AnnotatorNotes T3	C1707887; Efficacy Study; Research Activity
T4	DISO 148 170	infección por COVID-19
#3	AnnotatorNotes T4	C5203670; COVID19 (disease); Disease or Syndrome
T5	DISO 210 228	Infección COVID-19
T6	PROC 241 256	hospitalización
#4	AnnotatorNotes T6	C0019993; Hospitalization; Health Care Activity
T7	DISO 303 311	COVID-19
#5	AnnotatorNotes T7	C5203670; COVID19 (disease); Disease or Syndrome
T8	DISO 344 365	Neumonía intersticial
#6	AnnotatorNotes T8	C0206061; Pneumonia, Interstitial; Disease or Syndrome
T9	PROC 390 397	ingreso
#7	AnnotatorNotes T9	C0021629; Institutionalization; Health Care Activity | C0184666; Hospital admission; Health Care Activity
T10	DISO 446 452	Fiebre
#8	AnnotatorNotes T10	C0015967; Fever; Sign or Symptom
T11	ANAT 465 469	oído
#9	AnnotatorNotes T11	C0013443; Ear structure; Body Part, Organ, or Organ Component | C0521421; Entire ear; Body Part, Organ, or Organ Component
T12	CHEM 473 477	IL-6
#10	AnnotatorNotes T12	C0021760; interleukin-6; Amino Acid, Peptide, or Protein · Immunologic Factor | C1698754; IL6 protein, human; Amino Acid, Peptide, or Protein · Biologically Active Substance | C2983957; interleukin-6, human; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	ANAT 481 486	suero
#11	AnnotatorNotes T13	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T14	CHEM 530 540	prednisona
#12	AnnotatorNotes T14	C0032952; prednisone; Hormone · Organic Chemical · Pharmacologic Substance
T15	CHEM 1568 1577	sarilumab
#13	AnnotatorNotes T15	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T16	PROC 583 593	Linfocitos
#14	AnnotatorNotes T16	C0200635; Lymphocyte Count measurement; Laboratory Procedure
T17	CHEM 1732 1741	sarilumab
#15	AnnotatorNotes T17	C3885145; sarilumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T18	PROC 725 733	D-dímero
T19	PROC 747 771	Consentimiento informado
#16	AnnotatorNotes T19	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T20	PROC 910 930	ventilación mecánica
#17	AnnotatorNotes T20	C0199470; Mechanical ventilation; Therapeutic or Preventive Procedure
T21	PROC 962 976	Valores de AST
T22	PROC 1044 1066	Valores de neutrófilos
T23	ANAT 1085 1092	células
#18	AnnotatorNotes T23	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T24	PROC 1100 1120	Valores de plaquetas
T25	ANAT 1140 1147	células
#19	AnnotatorNotes T25	C0007634; Cells; Cell | C1269647; Entire cell; Cell
T26	DISO 1156 1162	Sepsis
#20	AnnotatorNotes T26	C0243026; Sepsis; Disease or Syndrome
T27	DISO 1224 1232	COVID-19
#21	AnnotatorNotes T27	C5203670; COVID19 (disease); Disease or Syndrome
T28	DISO 1250 1264	comorbilidades
#22	AnnotatorNotes T28	C1275743; Co-morbid conditions; Finding
T29	DISO 1338 1352	Diverticulitis
#23	AnnotatorNotes T29	C0012813; Diverticulitis; Disease or Syndrome | C0349774; Diverticulitis of gastrointestinal tract; Disease or Syndrome
T30	DISO 1366 1388	perforación intestinal
#24	AnnotatorNotes T30	C0021845; Intestinal Perforation; Disease or Syndrome
T31	DISO 1393 1410	Infección cutánea
T32	PROC 1463 1499	Terapia inmunosupresora anti-rechazo
T33	CHEM 1471 1486	inmunosupresora
#25	AnnotatorNotes T33	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
T34	PROC 1531 1542	Tratamiento
#26	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	CHEM 1554 1565	tocilizumab
#27	AnnotatorNotes T35	C1609165; tocilizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T36	PROC 1620 1634	ensayo clínico
#28	AnnotatorNotes T36	C0008976; Clinical Trials; Research Activity
T37	DISO 1640 1664	infección por SARS-CoV-2
#29	AnnotatorNotes T37	C5203670; COVID19 (disease); Disease or Syndrome
T38	DISO 1427 1443	dermopiodermitis
T39	DISO 1684 1701	hipersensibilidad
#30	AnnotatorNotes T39	C0020517; Hypersensitivity; Pathologic Function | C0429891; Hypersensitivity finding; Finding
T40	CHEM 1744 1755	excipientes
#31	AnnotatorNotes T40	C0015237; Pharmaceutical Excipient; Biomedical or Dental Material
T41	PROC 337 340	PCR
#32	AnnotatorNotes T41	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T42	ANAT 353 365	intersticial
#33	AnnotatorNotes T42	C0596790; interstitial; Body Location or Region | C2328510; Interstitium; Body Part, Organ, or Organ Component
T43	PROC 473 486	IL-6 en suero
T44	PROC 568 571	PCR
#34	AnnotatorNotes T44	C0032520; Polymerase Chain Reaction; Molecular Biology Research Technique
T45	PROC 607 616	Ferritina
#35	AnnotatorNotes T45	C0373607; Ferritin measurement; Laboratory Procedure
T46	PROC 658 667	Ferritina
#36	AnnotatorNotes T46	C0373607; Ferritin measurement; Laboratory Procedure
T47	PROC 709 712	LDH
#37	AnnotatorNotes T47	C0202113; Lactate dehydrogenase measurement; Laboratory Procedure
T48	PROC 784 822	administración en condiciones urgentes
T49	CHEM 973 976	AST
#38	AnnotatorNotes T49	C0004002; Aspartate Transaminase; Amino Acid, Peptide, or Protein · Enzyme
T50	PROC 979 982	ALT
#39	AnnotatorNotes T50	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T51	ANAT 1055 1066	neutrófilos
#40	AnnotatorNotes T51	C0027950; neutrophil; Cell
T52	ANAT 1111 1120	plaquetas
#41	AnnotatorNotes T52	C0005821; Blood Platelets; Cell
T53	ANAT 1378 1388	intestinal
#42	AnnotatorNotes T53	C0021853; Intestines; Body Part, Organ, or Organ Component | C1318303; Entire intestine; Body Part, Organ, or Organ Component
T54	ANAT 1403 1410	cutánea
#43	AnnotatorNotes T54	C0011646; Dermis; Tissue | C1123023; Skin; Body System
T55	Date 13 17	2020
T56	Route 120 130	subcutáneo
T57	LIVB 134 143	pacientes
#44	AnnotatorNotes T57	C0030705; Patients; Patient or Disabled Group
T58	Age 290 299	> 18 años
T59	Neg_cue 502 513	ausencia de
T61	Dose 555 564	> 1 mg/kg
T64	Duration 646 654	24 horas
T69	LIVB 886 895	Pacientes
#45	AnnotatorNotes T69	C0030705; Patients; Patient or Disabled Group
T70	Spec_cue 1182 1190	sospecha
T71	Date 1411 1417	actual
T73	PHYS 1505 1513	Embarazo
#46	AnnotatorNotes T73	C0032961; Pregnancy; Organism Function
T74	PHYS 1516 1525	lactancia
#47	AnnotatorNotes T74	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T75	LIVB 1583 1592	Pacientes
#48	AnnotatorNotes T75	C0030705; Patients; Patient or Disabled Group
T76	LIVB 1670 1679	Pacientes
#49	AnnotatorNotes T76	C0030705; Patients; Patient or Disabled Group
T78	LIVB 1201 1210	patógenos
#50	AnnotatorNotes T78	C0450254; Pathogenic organism; Organism
T60	LIVB 1654 1664	SARS-CoV-2
#51	AnnotatorNotes T60	C5203676; SARS-CoV-2; Virus
T62	Neg_cue 1211 1223	distintos de
A1	Assertion T14 Negated
A2	Assertion T26 Speculated
A3	Assertion T27 Negated
A4	Status T14 History_of
A5	Status T34 History_of
A6	Status T35 History_of
A7	Status T15 History_of
A8	Status T39 History_of
A9	Assertion T17 Contraindicated
A10	Assertion T40 Contraindicated
#52	AnnotatorNotes T1	C0031928; Pilot Projects; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#53	AnnotatorNotes T5	C5203670; COVID19 (disease); Disease or Syndrome
#54	AnnotatorNotes T56	C1522438; Subcutaneous Route of Drug Administration; Functional Concept
#55	AnnotatorNotes T43	C2208839; serum interleukin-6; Laboratory Procedure
#56	AnnotatorNotes T18	C2826333; D-Dimer Measurement; Laboratory Procedure 
#57	AnnotatorNotes T22	C0200633; Neutrophil count (procedure); Laboratory Procedure 
#58	AnnotatorNotes T24	C0032181; Platelet Count measurement; Laboratory Procedure
#59	AnnotatorNotes T31	C0037278; Skin Diseases, Infectious; Disease or Syndrome 
#60	AnnotatorNotes T21	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
#61	AnnotatorNotes T71	C0521116; Current (present time); Temporal Concept 
T63	Quantifier_or_Qualifier 1447 1457	controlada
A11	Assertion T63 Negated
T65	Neg_cue 1444 1446	no
R1	Has_Route_or_Mode Arg1:T2 Arg2:T56	
R2	Experiences Arg1:T57 Arg2:T2	
R3	Experiences Arg1:T57 Arg2:T4	
T66	Quantifier_or_Qualifier 171 185	moderada-grave
#62	AnnotatorNotes T66	C1299393; Moderate to severe; Qualitative Concept
R4	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T66	
T67	Result_or_Value 312 320	positivo
#63	AnnotatorNotes T67	C1446409; Positive; Finding
R6	Causes Arg1:T7 Arg2:T67	
R7	Has_Result_or_Value Arg1:T41 Arg2:T67	
R8	Location_of Arg1:T42 Arg2:T8	
R9	Location_of Arg1:T11 Arg2:T10	
T68	Result_or_Value 453 461	≥ 37,8ºC
R10	Has_Result_or_Value Arg1:T10 Arg2:T68	
R11	Location_of Arg1:T13 Arg2:T43	
T72	Result_or_Value 487 497	≥ 25 ng/mL
R12	Has_Result_or_Value Arg1:T43 Arg2:T72	
R13	Negation Arg1:T59 Arg2:T14	
T77	CONC 530 540;543 554	prednisona equivalente
R14	Has_Dose_or_Strength Arg1:T14 Arg2:T61	
R15	Has_Dose_or_Strength Arg1:T77 Arg2:T61	
A12	Assertion T77 Negated
R16	Negation Arg1:T59 Arg2:T77	
T79	Result_or_Value 572 579	>5mg/dL
R17	Has_Result_or_Value Arg1:T44 Arg2:T79	
T80	Result_or_Value 594 603	< 600 mm3
R18	Has_Result_or_Value Arg1:T16 Arg2:T80	
T81	Result_or_Value 617 642	>300 mcg/L que se duplica
R19	After Arg1:T45 Arg2:T64	
R20	Has_Result_or_Value Arg1:T45 Arg2:T81	
T82	Result_or_Value 713 721	>250 U/L
R21	Has_Result_or_Value Arg1:T47 Arg2:T82	
T83	Result_or_Value 668 678	>600 mcg/L
R22	Has_Result_or_Value Arg1:T46 Arg2:T83	
T84	Quantifier_or_Qualifier 685 706	primera determinación
R23	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T84	
T85	Quantifier_or_Qualifier 772 778	verbal
#64	AnnotatorNotes T85	C0439824; Verbal; Qualitative Concept
R24	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T85	
T86	Result_or_Value 735 742	>1 mg/L
R25	Has_Result_or_Value Arg1:T18 Arg2:T86	
T87	CONC 839 855	historia clínica
#66	AnnotatorNotes T87	C5204342; Clinical History; Intellectual Product
R28	Experiences Arg1:T69 Arg2:T20	
T88	CONC 948 957	inclusión
#65	AnnotatorNotes T88	C1512693; Inclusion; Qualitative Concept
R29	Overlap Arg1:T20 Arg2:T88	
T89	Result_or_Value 983 1039	superiores a 5 veces el límite superior de la normalidad
R30	Has_Result_or_Value Arg1:T21 Arg2:T89	
R31	Has_Result_or_Value Arg1:T50 Arg2:T89	
T90	Result_or_Value 1067 1096	por debajo de 500 células/mm3
R32	Has_Result_or_Value Arg1:T22 Arg2:T90	
T91	Result_or_Value 1124 1152	menos de 50.000 células /mm3
R33	Has_Result_or_Value Arg1:T24 Arg2:T91	
R34	Speculation Arg1:T70 Arg2:T26	
R35	Causes Arg1:T78 Arg2:T26	
R36	Negation Arg1:T62 Arg2:T27	
R37	Overlap Arg1:T26 Arg2:T27	
T92	Observation 1311 1333	resultado desfavorable
#67	AnnotatorNotes T92	C0278252; Prognosis bad; Finding
R38	Before Arg1:T28 Arg2:T92	
R39	Location_of Arg1:T53 Arg2:T30	
T93	Quantifier_or_Qualifier 1353 1363	complicada
#68	AnnotatorNotes T93	C0231242; Complicated; Functional Concept 
R40	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T93	
R41	Location_of Arg1:T54 Arg2:T31	
R42	Overlap Arg1:T31 Arg2:T71	
R43	Negation Arg1:T65 Arg2:T63	
R44	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T63	
R45	Used_for Arg1:T33 Arg2:T32	
#69	AnnotatorNotes T32	C0021079; Therapeutic immunosuppression; Therapeutic or Preventive
R46	Used_for Arg1:T35 Arg2:T34	
R47	Used_for Arg1:T15 Arg2:T34	
T94	Observation 1593 1634	participando en algún otro ensayo clínico
R49	Experiences Arg1:T75 Arg2:T37	
R50	Causes Arg1:T60 Arg2:T37	
R51	Experiences Arg1:T76 Arg2:T39	
R52	Causes Arg1:T17 Arg2:T39	
R53	Causes Arg1:T40 Arg2:T39	
R54	Before Arg1:T14 Arg2:T43	
R55	Before Arg1:T77 Arg2:T43	
#70	AnnotatorNotes T38	C1696849; Dermo-hypodermitis; Disease or Syndrome (?) 
A13	Experiencer T57 Patient
A14	Experiencer T69 Patient
A15	Experiencer T75 Patient
A16	Experiencer T76 Patient
